524816

New Filing detected. See link for details.

New Filing detected. See link for details.

- Natco Pharma's Board approved an investment of ₹1400 Crores in Natco Pharma South Africa Proprietary Limited, its wholly-owned subsidiary. - The Board also approved increasing its stake in Adcock Ingram Holdings Proprietary Limited from 35.75% to 49% for ₹1069 Crores. - This strategic investment aims to expand the geographic footprint and increase profitability, with completion expected by July 2026.

- Mr. Gnanadeva Chalapathy Gudipati designated as Senior Vice President - Analytical Research & Development. - Mr. Madhava Rao Karicherla designated as Vice President – Formulation Research & Development, Pharma Division, Kothur Unit. - The designations are effective from 6th July, 2026.

- Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division, superannuated effective from the closure of business hours on June 30, 2026.

- Trading window for dealing in the company's securities will be closed from July 1, 2026. - It will reopen 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. - The Board Meeting date for results will be announced later.

- The company reported a decline in consolidated total revenue for FY26 to ₹4,375.9 crores (from ₹4,784 crores in FY25) and net profit to ₹1,418.5 crores (from ₹1,883.4 crores in FY25), mainly due to the impact of Revlimid and increased freight expenses. - Management guided for a further significant decline in FY27, with expected revenue of ₹3,400-3,500 crores and PAT of ₹700-750 crores, a substantial reduction from FY26 actuals. - The tax rate for FY27-FY28 is expected to be around 25%, and R&D expenses are projected at 7-9% of earnings for the next year. - Beyond FY27, the company anticipates 15-25% compounded annual growth, driven by new exclusivities and product launches in Brazil and Canada, aiming for more stable, diversified earnings. - Key initiatives include geographical diversification through acquisitions (Brazil, Canada, South Africa, India) with ~₹2,400 crores net cash for M&A, and the semaglutide launch targeting ₹75-100 crores annualized. - The Crop Health Sciences business grew to ₹140 crores in FY26 (from ₹60 crores in FY25) and is in the process of demerger.

- NATCO Pharma Limited and Lupin Limited received approval from the U.S. FDA for Eribulin Mesylate Injection, 1 mg/2ml (0.5 mg/ml) Single-Dose Vials. - This injection is bioequivalent to Halaven® Injection and is indicated for metastatic breast cancer and liposarcoma. - The reference listed drug had estimated annual sales of USD 43.7 million in the U.S. (IQVIA MAT April 2026).

Natco Pharma Limited informed the exchanges about the enclosure of the transcript of its earnings conference call for Q4 FY25-26, which was held on May 29, 2026. The transcript is also available on the company's website.

Consolidated Revenue ₹739.1Cr vs ₹1,221.0Cr (▼39.5% YoY), EBITDA ₹127.6Cr vs ₹548.1Cr (▼76.7% YoY), PAT ₹269.0Cr vs ₹406.0Cr (▼33.7% YoY), with EBITDA Margin 15.62% vs 44.89% (▼2927bps); the Q4 PAT includes a one-time deferred tax asset benefit of ₹115.0Cr.

Consolidated Revenue from operations for Q4 FY26 was ₹739.1Cr vs ₹1,221.0Cr (▼39.5% YoY), EBITDA was ₹127.6Cr vs ₹548.1Cr (▼76.7% YoY), and PAT was ₹269.0Cr vs ₹406.0Cr (▼33.7% YoY). EBITDA Margin contracted from 44.9% to 17.3% (▼2760bps). The net profit for the quarter includes a one-time benefit of ₹115Cr from moving to a new tax regime and re-measuring deferred tax assets.

Natco Pharma Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as per Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report confirms overall compliance with applicable statutory provisions. It noted that some related party transactions lacked prior audit committee approval but were subsequently ratified by the Audit Committee and Board of Directors. The report also stated that no actions were taken against the company by SEBI or stock exchanges during the review period.